These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 15582280)
41. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Ritchie CW; Bush AI; Mackinnon A; Macfarlane S; Mastwyk M; MacGregor L; Kiers L; Cherny R; Li QX; Tammer A; Carrington D; Mavros C; Volitakis I; Xilinas M; Ames D; Davis S; Beyreuther K; Tanzi RE; Masters CL Arch Neurol; 2003 Dec; 60(12):1685-91. PubMed ID: 14676042 [TBL] [Abstract][Full Text] [Related]
42. The distribution profile and oxidation states of biometals in APP transgenic mouse brain: dyshomeostasis with age and as a function of the development of Alzheimer's disease. Wang H; Wang M; Wang B; Li M; Chen H; Yu X; Zhao Y; Feng W; Chai Z Metallomics; 2012 Mar; 4(3):289-96. PubMed ID: 22301945 [TBL] [Abstract][Full Text] [Related]
43. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. Huang X; Atwood CS; Moir RD; Hartshorn MA; Tanzi RE; Bush AI J Biol Inorg Chem; 2004 Dec; 9(8):954-60. PubMed ID: 15578276 [TBL] [Abstract][Full Text] [Related]
44. Screening a specific Zn(ii)-binding peptide for improving the cognitive decline of Alzheimer's disease in APP/PS1 transgenic mice by inhibiting Zn Zhang X; Zhong M; Zhao P; Zhang X; Li Y; Wang X; Sun J; Lan W; Sun H; Wang Z; Gao H Biomater Sci; 2019 Nov; 7(12):5197-5210. PubMed ID: 31588929 [TBL] [Abstract][Full Text] [Related]
45. Effect of poly(propylene imine) glycodendrimers on β-amyloid aggregation in vitro and in APP/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheimer's disease. Klementieva O; Aso E; Filippini D; Benseny-Cases N; Carmona M; Juvés S; Appelhans D; Cladera J; Ferrer I Biomacromolecules; 2013 Oct; 14(10):3570-80. PubMed ID: 24004423 [TBL] [Abstract][Full Text] [Related]
46. A Preliminary Study of Cu Exposure Effects upon Alzheimer's Amyloid Pathology. Pilozzi A; Yu Z; Carreras I; Cormier K; Hartley D; Rogers J; Dedeoglu A; Huang X Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32155778 [TBL] [Abstract][Full Text] [Related]
47. Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation. Choi JS; Braymer JJ; Park SK; Mustafa S; Chae J; Lim MH Metallomics; 2011 Mar; 3(3):284-91. PubMed ID: 21210061 [TBL] [Abstract][Full Text] [Related]
49. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Duce JA; Bush AI Prog Neurobiol; 2010 Sep; 92(1):1-18. PubMed ID: 20444428 [TBL] [Abstract][Full Text] [Related]
50. Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease. Huang M; Xie SS; Jiang N; Lan JS; Kong LY; Wang XB Bioorg Med Chem Lett; 2015 Feb; 25(3):508-13. PubMed ID: 25542589 [TBL] [Abstract][Full Text] [Related]
51. Therapeutic redistribution of metal ions to treat Alzheimer's disease. Crouch PJ; Barnham KJ Acc Chem Res; 2012 Sep; 45(9):1604-11. PubMed ID: 22747493 [TBL] [Abstract][Full Text] [Related]
52. Two functions, one molecule: a metal-binding and a targeting moiety to combat Alzheimer's disease. Hureau C; Sasaki I; Gras E; Faller P Chembiochem; 2010 May; 11(7):950-3. PubMed ID: 20401891 [No Abstract] [Full Text] [Related]
53. Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. Huang L; Lu C; Sun Y; Mao F; Luo Z; Su T; Jiang H; Shan W; Li X J Med Chem; 2012 Oct; 55(19):8483-92. PubMed ID: 22978824 [TBL] [Abstract][Full Text] [Related]
54. Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis. Zhang J; Liu Q; Chen Q; Liu NQ; Li FL; Lu ZB; Qin C; Zhu H; Huang YY; He W; Zhao BL FASEB J; 2006 Jun; 20(8):1212-4. PubMed ID: 16627626 [TBL] [Abstract][Full Text] [Related]
55. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. Zheng H; Youdim MB; Fridkin M J Med Chem; 2009 Jul; 52(14):4095-8. PubMed ID: 19485411 [TBL] [Abstract][Full Text] [Related]
56. The metallobiology of Alzheimer's disease. Bush AI Trends Neurosci; 2003 Apr; 26(4):207-14. PubMed ID: 12689772 [TBL] [Abstract][Full Text] [Related]
57. Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. Di Fede G; Catania M; Maderna E; Morbin M; Moda F; Colombo L; Rossi A; Cagnotto A; Virgilio T; Palamara L; Ruggerone M; Giaccone G; Campagnani I; Costanza M; Pedotti R; Salvalaglio M; Salmona M; Tagliavini F Sci Rep; 2016 Feb; 6():20949. PubMed ID: 26864599 [TBL] [Abstract][Full Text] [Related]
58. Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. Fasae KD; Abolaji AO; Faloye TR; Odunsi AY; Oyetayo BO; Enya JI; Rotimi JA; Akinyemi RO; Whitworth AJ; Aschner M J Trace Elem Med Biol; 2021 Sep; 67():126779. PubMed ID: 34034029 [TBL] [Abstract][Full Text] [Related]
59. Metal complexing agents as therapies for Alzheimer's disease. Bush AI Neurobiol Aging; 2002; 23(6):1031-8. PubMed ID: 12470799 [TBL] [Abstract][Full Text] [Related]
60. Novel drug targets based on metallobiology of Alzheimer's disease. Bandyopadhyay S; Huang X; Lahiri DK; Rogers JT Expert Opin Ther Targets; 2010 Nov; 14(11):1177-97. PubMed ID: 20942746 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]